Showing 3211-3220 of 5646 results for "".
- Bausch Health Initiates Second Phase 3 Study for Investigational Treatment for Dry Eye Disease Associated With MGDhttps://modernod.com/news/bausch-health-initiates-second-phase-3-study-for-nov03-investigational-treatment-for-dry-eye-disease-associated-with-meibomian-gland-dysfunction/2478590/Bausch + Lomb announced the initiation of the second of two phase 3 studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a first-in-class investigational drug with a novel mechanism of action to treat the signs and symptoms of dry eye disease (DED) associated with meib
- Oculus Names New Medical Directorhttps://modernod.com/news/oculus-names-new-medical-director/2478589/Oculus has announced that William Tullo, OD, FAAO, joined the company as a Medical Director on November 2nd, 2020. In this newly developed role, Dr. Tullo will provide clinical guidance and educate medical eye profess
- Despite Impressive Data, FDA’s Coronavirus Vaccine Reviews Will Take Weeks, Not Days, Official Sayshttps://modernod.com/news/despite-impressive-data-fdas-coronavirus-vaccine-reviews-will-take-weeks-not-days-official-says/2478574/As leading COVID-19 vaccines post positive phase 3 data and near FDA submissions, the agency official in charge of reviewing vaccines is emphasizing transparency and patience during the high-stakes process, according to a FiercePharma
- Pfizer, BioNTech’s COVID-19 Vaccine Shows 95% Efficacy Rate at Final Analysishttps://modernod.com/news/pfizer-biontechs-covid-19-vaccine-shows-95-efficacy-rate-at-final-analysis/2478571/Pfizer and BioNTech announced Wednesday that their mRNA-based COVID-19 vaccine candidate BNT162b2 demonstrated an efficacy rate of 95% at the final efficacy analysis of a phase 3 study. The companies noted the primary objective analysis is based on 170 cases of COVID-19, of which 162 cases were o
- Alcon Canada Introduces AcrySof IQ Vivity Presbyopia-Correcting IOLhttps://modernod.com/news/alcon-canada-introduces-acrysof-iq-vivity-presbyopia-correcting-iol/2478568/Alcon has announced the Canadian launch of AcrySof IQ Vivity presbyopia-correcting IOL. AcrySof IQ Vivity uses a non-diffractive design called X-WAVE technology and provides an extended range of vision and reduced dependency on glasses following cataract surgery.
- IRIS Registry Reveals Insights into Eye Disease Prevention and Treatmenthttps://modernod.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/The IRIS Registry powered a number of big data studies this year, many of which were presented at AAO 2020 Virtual, the 124th annual meeting of the American Academy of Ophthalmology. The research findings are now available to view on demand. “With a growing pool of aggregated d
- Moderna Says mRNA COVID-19 Vaccine 94.5% Effectivehttps://modernod.com/news/moderna-says-mrna-covid-19-vaccine-94-5-effective/2478555/Moderna announced Monday that in the first interim analysis of the phase 3 COVE study, its experimental COVID-19 vaccine mRNA-1273 demonstrated efficacy of 94.5%. The company noted that the analysis was based on 95 cases of coronavirus infection, of which 90 cases were observed in the placebo gro
- EyeMD EMR 2.0 All-in-One Platform Unveiled at AAO Virtualhttps://modernod.com/news/eyemd-emr-healthcare-systems-to-unveil-the-eyemd-emr-2-0-all-in-one-platform-at-aao-virtual/2478542/EyeMD EMR Healthcare Systems will debut EyeMD EMR 2.0, an all-in-one EMR, PM, and PACS system at the American Academy of Ophthalmology (AAO) Virtual Conference, taking place Nov. 13–15, 2020. EyeMD EMR 2.0 now includes EMR, PM and PACS functionality in one streamlined offering. EyeMD EMR P
- EU Seals Deal For Up to 300 Million Doses of Pfizer, BioNTech’s COVID-19 Vaccinehttps://modernod.com/news/eu-seals-deal-for-up-to-300-million-doses-of-pfizer-biontechs-covid-19-vaccine/2478528/The European Commission on Wednesday said it has finalized an advance purchase agreement with Pfizer and BioNTech for the initial supply of 200 million doses of their experimental COVID-19 vaccine, with an option to request up to a 100 million more. The announcement comes days after the companies
- Nicox Initiates Second Phase 3 Trial of NCX 470 in Glaucomahttps://modernod.com/news/nicox-initiates-second-phase-3-trial-of-ncx-470-in-glaucoma/2478515/Nicox announced the initiation of the second phase 3 clinical trial of NCX 470 (Denali) evaluating NCX 470 for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. The first patients were enrolled in the U.S. on November 9, 2020. NCX 470, Nicox’s lead clinical p